A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers (Q40776375)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers |
scientific article |
Statements
1 reference
A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers (English)
1 reference
Johanna C Bendell
1 reference
Ahmed Zakari
1 reference
Evan Lang
1 reference
David Waterhouse
1 reference
Douglas Flora
1 reference
Kathryn Alguire
1 reference
Michael McCleod
1 reference
Nancy Peacock
1 reference
Peter Ruehlman
1 reference
Cassie M Lane
1 reference
Chris Earwood
1 reference
Kent Shih
1 reference
29 April 2016
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference